A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results (1) from the phase 3 M14TIL trial reported on September 10 at the European Society for Medical Oncology ESMO Congress 2022 in Paris, September 9-13.The presentation was titled “Treatment with Tumor Infiltrating Lymphocytes (TIL) Versus Ipilimumab (IPI) for Advanced Melanoma: Results from a Multicenter, Randomized Phase 3 Trial.”“This study shows, for the first time in a randomized controlled trial, that cell therapy can be efficacious and beneficial for patients with solid cancers,” said lead author John Haanen, MD, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands.